107 search results for: burden of disease
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.
Epidemiology and Pathophysiology of AD in Children
In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses the epidemiology of AD in children and the role of type 2 cytokines in driving the pathophysiology of the disease
What Differentiates COPD Exacerbations From Asthma Exacerbations?
Join global expert Dr. Eric Bateman as he discusses how exacerbations in patients with COPD are different than exacerbations in patients with asthma.
What proportion of patients can achieve control in CRSwNP?
Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime
Join ADVENT faculty members Len Bacharier, Antonella Cianferoni, and Andre Moreira for an educational symposium highlighting type 2 inflammation and its shared and distinct roles in multiple chronic pediatric diseases.
EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Join Professor Joaquim Mullol for a discussion of the emerging concept of clinical remission in CRSwNP.
World Anosmia Awareness Day
Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.
Partnering With Patients: Scores That Matter in CRSwNP
Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life
Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.
Clinical Utility of Biomarkers in the Management of AD
Dr. Amy Paller discusses the clinical utility of TARC measurements in AD management at EADV 2025
